Analyzing Glaukos (NYSE:GKOS) & Iradimed (NASDAQ:IRMD)

Glaukos (NYSE:GKOS – Get Free Report) and Iradimed (NASDAQ:IRMD – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Glaukos and Iradimed’s net margins, return on equity and return on assets.

Risk & Volatility

Glaukos has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Valuation & Earnings

This table compares Glaukos and Iradimed”s revenue, earnings per share (EPS) and valuation.

Iradimed has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 6.4% of Glaukos shares are owned by insiders. Comparatively, 42.6% of Iradimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Glaukos and Iradimed, as provided by MarketBeat.com.

Glaukos currently has a consensus price target of $130.45, suggesting a potential downside of 2.19%. Iradimed has a consensus price target of $60.00, suggesting a potential upside of 15.81%. Given Iradimed’s stronger consensus rating and higher possible upside, analysts plainly believe Iradimed is more favorable than Glaukos.

Summary

Iradimed beats Glaukos on 9 of the 14 factors compared between the two stocks.

About Glaukos

(Get Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

About Iradimed

(Get Free Report)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.